Laquinimod reduces neuroaxonal injury through inhibiting microglial activation

OBJECTIVE: Laquinimod is an emerging oral medication for multiple sclerosis (MS) that reduces brain atrophy and progression of disability in two Phase III clinical trials. The mechanism of these effects is unclear. Persistent activation of microglia occurs in MS and contributes to injury. Thus, we i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mishra, Manoj Kumar, Wang, Janet, Keough, Michael B, Fan, Yan, Silva, Claudia, Sloka, Scott, Hayardeny, Liat, Brück, Wolfgang, Yong, V Wee
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2014
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4184669/
https://ncbi.nlm.nih.gov/pubmed/25356411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.67
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados